{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:11:14Z","timestamp":1791889874840,"version":"4.3.4"},"reference-count":54,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,5,28]],"date-time":"2015-05-28T00:00:00Z","timestamp":1432771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:p>Glucocorticosteroids are a group of structurally related molecules that includes natural hormones and synthetic drugs with a wide range of anti\u2010inflammatory potencies. For synthetic corticosteroid analogues it is commonly assumed that the therapeutic index cannot be improved by increasing their glucocorticoid receptor binding affinity. The validity of this assumption, particularly for inhaled corticosteroids, has not been fully explored. Inhaled corticosteroids exert their anti\u2010inflammatory activity locally in the airways, and hence this can be dissociated from their potential to cause systemic adverse effects. The molecular structural features that increase glucocorticoid receptor binding affinity and selectivity drive topical anti\u2010inflammatory activity. However, in addition, these structural modifications also result in physicochemical and pharmacokinetic changes that can enhance targeting to the airways and reduce systemic exposure. As a consequence, potency and therapeutic index can be correlated. However, this consideration is not reflected in asthma treatment guidelines that classify inhaled corticosteroid formulations as low\u2010, mid\u2010 and high dose, and imbed a simple dose equivalence approach where potency is not considered to affect the therapeutic index. This article describes the relationship between potency and therapeutic index, and concludes that higher potency can potentially improve the therapeutic index. Therefore, both efficacy and safety should be considered when classifying inhaled corticosteroid regimens in terms of dose equivalence. The historical approach to dose equivalence in asthma treatment guidelines is not appropriate for the wider range of molecules, potencies and device\/formulations now available. A more robust method is needed that incorporates pharmacological principles.<\/jats:p>","DOI":"10.1111\/bcp.12637","type":"journal-article","created":{"date-parts":[[2015,3,24]],"date-time":"2015-03-24T22:09:41Z","timestamp":1427234981000},"page":"372-380","source":"Crossref","is-referenced-by-count":224,"title":["Inhaled corticosteroids: potency, dose equivalence and therapeutic index"],"prefix":"10.1111","volume":"80","author":[{"given":"Peter T.","family":"Daley\u2010Yates","sequence":"first","affiliation":[{"name":"Clinical Pharmacology, GlaxoSmithKline Research and Development  Uxbridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,5,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003258651"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(98)70004-1"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.153.6.8665030"},{"key":"e_1_2_8_5_1","first-page":"273","volume-title":"Respiratory Drug Delivery","author":"Daley\u2010Yates PT","year":"2010"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04262.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(72)91094-X"},{"key":"e_1_2_8_8_1","first-page":"1","volume-title":"Exogenous Glucocorticoids in Paediatric Asthma","author":"Daley\u2010Yates PT","year":"2007"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-8-54"},{"issue":"1","key":"e_1_2_8_10_1","first-page":"8","article-title":"Absorption kinetics after inhalation of fluticasone propionate via the Diskhaler, Diskus and metered\u2010dose inhaler in healthy subjects","volume":"39","author":"Brindley C","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(97)90102-5"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1152\/ajplung.00108.2007","article-title":"Pharmacological properties of the enhanced\u2010affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease","volume":"293","author":"Salter M","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2011.08.022"},{"key":"e_1_2_8_14_1","first-page":"A73","article-title":"Cellular uptake and fatty acid esterification of budesonide and ciclesonide in protein\u2010rich medium","volume":"3","author":"Jerre A","year":"2006","journal-title":"Proc Am Thoracic Society"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1155\/2000\/464639","article-title":"Comparison of once\u2010 with twice\u2010daily dosing of fluticasone propionate in mild and moderate asthma","volume":"7","author":"Boulet LP","year":"2000","journal-title":"Can Respir J"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-160"},{"key":"e_1_2_8_17_1","first-page":"163","article-title":"Relationship between pharmacokinetic and aerodynamic particle size distribution properties for inhalers containing corticosteroids","volume":"1","author":"Daley\u2010Yates PT","year":"2014","journal-title":"Respiratory Drug Delivery"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.04.00076604"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7307.253"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAF.0b013e31823d29ad"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2005.052456"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.12.030"},{"key":"e_1_2_8_23_1","first-page":"19\u2013","volume-title":"Exogenous Glucocorticoids in Paediatric Asthma, eds Wolthers OD","author":"Wolthers OD","year":"2007"},{"key":"e_1_2_8_24_1","first-page":"A518","article-title":"A physiologically based pharmacokinetic\/pharmacodynamic model predicting cortisol suppression for inhaled corticosteroids","volume":"163","author":"Daley\u2010Yates PT","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62918-3"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.4.97-03029"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)88292-2"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122012913"},{"issue":"30","key":"e_1_2_8_29_1","first-page":"P1358","article-title":"Beclomethasone dipropionate chlorofluorocarbon and hydrofluoroalkane metered dose inhalers: relationship between systemic exposure, dose, fine particle mass and particle size in healthy volunteers","volume":"14","author":"Daley\u2010Yates PT","year":"1999","journal-title":"Eur Resp J"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2005.01.004"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.1.70"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80113-2"},{"key":"e_1_2_8_33_1","first-page":"A354","article-title":"Pharmacokinetics and pharmacodynamics of fluticasone propionate and mometasone furoate dry powder inhalers in healthy and asthmatic subjects","volume":"2","author":"Daley\u2010Yates PT","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0078-1"},{"key":"e_1_2_8_35_1","unstructured":"FFA103096.A randomised double blind placebo controlled incomplete block five\u2010way cross\u2010over study to investigate the effect of one week repeat dosing of fluticasone furoate (GW685698X) and fluticasone propionate (FP) on twenty\u2010four hour serum cortisol in healthy subjects. Study Period: October 2004 \u2013 March 2005. Available athttp:\/\/www.gsk\u2010clinicalstudyregister.com (last accessed 8 March 2015)."},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02581-2"},{"issue":"1","key":"e_1_2_8_37_1","first-page":"i1","article-title":"British guideline on the management of asthma","volume":"58","author":"British Thoracic Society and Scottish Intercollegiate Guidelines Network","year":"2003","journal-title":"Thorax"},{"key":"e_1_2_8_38_1","unstructured":"Global Initiative for Asthma.Global strategy for asthma management and prevention2014. Available athttp:\/\/www.ginasthma.org(last accessed 8 March 2015)."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-206260.367"},{"key":"e_1_2_8_40_1","first-page":"501\u2013","article-title":"Glucocorticoid receptors and fluticasone propionate","volume":"9","author":"Hogger P","year":"1998","journal-title":"Rev Contemp Pharmacother"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1994.tb02051.x"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200039001-00002"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2005.10.031"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(98)70156-3"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.03.003"},{"key":"e_1_2_8_46_1","first-page":"2442","article-title":"Quantitative structure\u2013pharmacokinetic\/pharmacodynamic relationships of corticosteroids in man","volume":"91","author":"Mager DE","year":"2001","journal-title":"J Pharm Sci"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200302-200OC"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200039001-00004"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.94.07101839"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.80.3.241"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199753020-00006"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1995.tb04064.x"},{"key":"e_1_2_8_53_1","first-page":"317","article-title":"Pharmacokinetics and pharmacodynamics of prednisolone after intravenous and oral administration","volume":"30","author":"Barth J","year":"1992","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"e_1_2_8_54_1","unstructured":"Electronic Medicines Compendium. Datapharm Communications Limited 1999. Available athttps:\/\/www.medicines.org.uk\/emc(last accessed 8 March 2015)."},{"key":"e_1_2_8_55_1","unstructured":"FDA approved drug products. FDA center for drug evaluation and research office of communications division of online communications 2014. Available athttp:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda(last accessed 8 March 2015)."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12637","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12637","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.12637","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:09:55Z","timestamp":1696378195000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,28]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1111\/bcp.12637"],"URL":"https:\/\/doi.org\/10.1111\/bcp.12637","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,28]]}}}